In the course of our search for the gene responsible for X-linked cone-rod dystrophy (COD1), we constructed a physical map and contig (encompassing the region between DXS556 and DXS228), and identified sequences showing homologies to the expressed sequence tags (ESTs) that matched CRSP2 (EXLM1) transcript. We confirmed the expression of the CRSP2 gene in the retina and refined its exact genomic location between DXS1368 and DXS993. We demonstrated that the entire transcript is encoded within 31 exons. Primers were designed for mutation analysis of the exons by direct sequencing of PCR products from genomic DNA, and revealed no mutations in COD1 families. We subsequently excluded CRSP2 as a candidate for COD1 by demonstrating the causative mutations in the RPGR. However, due to its expression in different tissues and its contribution to transcriptional regulation, CRSP2 may be a candidate for other diseases that map to this region of the X chromosome.
Keywords: CRSP2; EXLM1; Xp11.4; Cone dystrophy; RPGR; Transcriptional regulation X-linked cone-rod dystrophy (COD1; MIM 304020) is a rare, progressive visual disease primarily affecting the cone photoreceptors (Pinckers and Timmerman, 1981; Pinckers and Deutman, 1987; Jacobson et al., 1989) . In the course of our search for the COD1 gene (Hong et al., 1994; Seymour et al., 1998; Demirci et al., 2001) , we constructed a physical contig encompassing the region between DXS556 and DXS228 (Xp11.4), comprised of P1-derived artificial chromosomes (PACs), bacterial artificial chromosomes (BACs) and yeast artificial chromosomes (YACs). This complete physical contig was used for high throughput sequencing and BLAST searches to identify homologies with expressed sequence tags (ESTs) and cDNAs in GenBank. This enabled us to identify several EST hits (originating from different tissues including retina) that corresponded to CRSP2 transcript (NM_004229, 7984 nt) (MIM 300182, the cofactor required for Sp1 transcriptional activation subunit 2). This transcript was originally designated as EXLM1 (AB006651) when it was characterized and mapped to Xp11.2-p11.4 (Yoshikawa et al., 1998) .
Previous studies indicate that CRSP2 (EXLM1) is conserved through evolution in mammals and escapes X-chromosome inactivation (Yoshikawa et al., 1998) . The vitamin D receptor-interacting protein complex component DRIP150 and the thyroid hormone receptor-associated protein TRAP170 mRNAs are also identical to CRSP2 (EXLM1) mRNA, and were identified in multiprotein complexes involved in transcriptional regulation (Hittelman et al., 1999; Rachez et al., 1999; Ryu et al., 1999) . Therefore, as a potential candidate for COD1, we characterized CRSP2 (EXLM1) genomic structure and designed primers for mutation analysis of the exons in COD1 families.
We performed PCR with gene specific primers (forward: 5 0 -CCAATCTGGAGATTCCACATCAA-3 0 , reverse: 5 0 -TTAATAAGCGAATTGCATGG-3 0 ) to confirm the expression of the CRSP2 (EXLM1) gene in human retina using retina cDNA libraries, and to determine its exact genomic location on Xp11.4 using the genomic clones comprising our physical contig. The PCR conditions for genomic DNA amplification were: initial denaturation at 958C for 5 min, followed by 35 cycles of 45 s of denaturation at 958C, 10 s of annealing at 558C and 60 s of extension at 728C, and a final extension at 728C for 10 min. PCR was carried out in a 20 ul reaction volume containing 1 £ PCR buffer II, 1.5 mM MgCl 2 , 200 uM each dATP, dCTP, dGTP, dTTP, 0.5 uM each forward and reverse primer and 0.04 U/ul AmpliTaq Gold (Applied Biosystems, Foster City, CA). The retinal expression of the CRSP2 (EXLM1) gene was confirmed in two independent retina cDNA libraries (Fig.1) . The exact location of the gene was refined to be between DXS1368 and DXS993 on Xp11.4 (the order is tel-DXS556-DXS8042-DXS6821-DXS1368-CRSP2 (EXLM1)-DXS993-DXS228-cen). The physical map and contig spanning the region between the markers DXS6821 and DXS993 is shown in Fig. 2 .
The cDNA transcript was compared with the fragmented, high throughput genomic sequencing data from our contig to specify intron -exon junctions in silico. Two overlapping genomic clones [PAC16186 (AC093029) and RP11-169L17 (AC092474)] that were identified to harbor the entire CRSP2 (EXLM1) gene were further sequenced in order to obtain a complete genomic information. Thirty-one exons were determined and these exons were amplified and screened for mutations using the primers listed in Table I . CRSP2 (EXLM1) has a 4365-nt coding sequence (CDS: 120-4484) encoding a protein of 1453 amino acids (when the start and the stop codons are not considered). The coding region includes exons 2 through 30 and parts of the exons 1 and 31, indicating that all exons contribute to the translated protein. Although 5 0 UTR appears to be short, exon 31 contains a very long 3 0 UTR (3500 bp).
PCR primers flanking the exons were designed in order to generate PCR fragments that would also include the intron-exon junctions for detecting the splice site mutations (Table I ). The exons were amplified from leucocyte genomic DNA from six COD1-affected males (2 affected males from each of the 3 families) and two unaffected males, and screened for mutations by direct sequencing of PCR products in both strands with either ABI377 or ABI3700 automated sequencer. The PCR conditions for genomic DNA amplification were as follows: initial denaturation at 958C for 5 min, followed by 35 cycles of 45 s of denaturation at 958C, 10 s of annealing at 53 -588C (Table I) and 60 s of extension at 728C, and completed with a final extension at 728C for 10 min. PCR was done in a standard 50 ul reaction volume containing 1 £ PCR buffer II, 1.5 mM MgCl 2 , 200 uM each dATP, dCTP, dGTP, dTTP, 0.5 uM each forward and reverse primer, and 0.04 U/ul AmpliTaq Gold (Applied Biosystems). After gel checking, PCR products were purified using QIAquick PCR purification kit (Qiagen, Valencia, CA) and used as template for sequencing reactions. No causative mutations for COD1 were identified by the sequence analysis of the exons with the flanking intronic sequences. The sequence variants observed during our analyses were as follows: 644T. C (Asp175Asp), 815C. A (Ala232Ala), 3912T. G (Leu1265Val), 4471T. G (Val1451Gly) and 4769T. C (3 0 UTR). Four of these variants (644T. C, 3912T. G, 4471T. G, and 4769T. C) were detected both in affected and unaffected males. The search in dbSNP revealed two SNP cluster ID's for 4769T. C (rs3185561 and rs1128513). The allele frequencies for 644T. C and 815C. A in thirty X chromosomes from healthy female subjects were 0.76 and 0.03, respectively. 3912T. G and 4471T. G were observed in all chromosomes we screened (patients and healthy female subjects), indicating that the "T" allele that is present at these positions in some of the GenBank clones (but not detected in our samples) is either a rare allele in the North American population or a sequencing artifact.
There are currently eight mRNA sequences related to CRSP2 (EXLM1) in GenBank (AB006651.1, NM_004229.1, AF304448.1, AF135802.1, AF104256.1, AK023368.1, AF070563.1, AJ012077.1). AJ012077 represents an alternatively spliced form with the partial retention of intron 30 as the 3 0 end of the mRNA and is also confirmed with the identification of the overlapping ESTs in GenBank. BLAST search in the human EST database of GenBank using the full-length cDNA sequence (7984 nt) reveals over 300 EST hits from several different tissues including brain, eye, skin, lung, kidney, muscle (skeletal), prostate, ovary, colon, small intestine and bone marrow. Although our analyses of the exons and F.Y.K. DEMIRCI et al. 126 flanking intronic sequences did not reveal any disease-causing mutations, there remained the possibility of the mutations outside of these regions that could affect the splicing or stability of the RNA transcript. Nevertheless, we subsequently excluded CRSP2 (EXLM1) as a candidate, by remapping COD1 to Xp11.4-p21.1 and identifying the causative mutations in the RPGR exon ORF15 (Demirci et al., 2002) . However, the expression of CRSP2 (EXLM1) in retina and other tissues and its contribution to the transcriptional regulation, may be relevant for other diseases that map to this region of the X chromosome.
